Home » FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
The FDA has added dexamethasone to the list of drugs that may be compounded under its temporary policy allowing compounders to produce the drug during the COVID-19 pandemic.
Demand for the anti-inflammatory drug surged in mid-June after UK researchers reported that it reduced deaths in critically ill COVID-19 patients.
Five suppliers of dexamethasone are currently on the FDA’s drug shortages list — AuroMedics Pharma, Fresenius Kabi USA, Hikma Pharmaceuticals USA, Mylan Institutional and Somerset Therapeutics.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
20Jun
-
21Oct